menu
    • menu

    Company profile for Mitsubishi Tanabe Pharma

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in two business segments. The Medical Supplies segment is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Others segment is engaged in the manufacture, purchase and sale of chemical products, as well as the ...
    Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in two business segments. The Medical Supplies segment is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Others segment is engaged in the manufacture, purchase and sale of chemical products, as well as the management of real estate. As of March 31, 2014, the Company had 33 subsidiaries and five associated companies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mitsubishi Tanabe Pharmajapan Flag
    Country
    Country
    Japan
    Address
    Address
    Yodoyabashi Square 2-6-18, Kitahama, Chuo-kuOSAKA-SHI, OSK 541-8505
    Telephone
    Telephone
    +81-6-62055085
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mt-pharma.co.jp/e/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/mitsubishi-tanabe-pharma-corporation
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/mtpa_us?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 4916

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    BMS, J&J, Bayer lead 25,000+ pharma layoffs in 2024; Amylyx, FibroGen, Kronos Bio hit by trial failures, cash crunch

    Since 2022, there has been a significant surge in layoffs by pharmaceutical and biotech companies. While this trend continued into 2024, the industry showed signs of stabilization in the last four months of the year with the pace of layoffs slowing down. Nonetheless, 2024 was a challenging year. Data compiled by PharmaCompass indicates that over 25,000 layoffs were announced in 2024, driven by economic pressures, failed clinical trials, and strategic pivots. Bristol Myers Squibb and Johnson & Johnson led the layoffs with about 2,300 job cuts each. Bayer announced elimination of 1,800 positions.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available) US, Europe, China bear brunt of job cuts; Big Pharma hands pink slips to 10,000 Over 190 biopharma companies announced layoffs in 2024. The year began on a grim note — 27 firms announced significant job cuts in January 2024. By the yearend, Big Pharma alone had contributed more than 10,000 layoffs to the year’s total of over 25,000. Novartis announced over 1,200 job cuts in 2024. It eliminated 330 jobs after it acquired German biotech MorphoSys through the closure of sites in Munich and Boston. Similarly, Bayer announced significant reductions at its US and Swiss facilities.  North America saw increased retrenchments, especially at biotech hubs such as Boston, San Diego, and New Jersey. Massachusetts, with Boston and Cambridge as the epicenter of US biotechnology, saw around 4,000 layoffs, with companies like Relay Therapeutics, Editas Medicine, and Takeda driving the numbers. In San Diego, workforce reductions by Takeda, and Bavarian Nordic collectively resulted in over 900 job losses, significantly impacting the local biotech ecosystem. New Jersey was subject to broader restructuring efforts with BMS and Bayer contributing nearly 1,500 layoffs. The impact in Europe was equally severe. Germany, home to some of the world’s largest pharmaceutical companies, saw over 2,500 layoffs as Bayer and Boehringer Ingelheim scaled back operations. Novartis’ decision to shut down its Munich site added hundreds more to the tally. In Switzerland, Idorsia eliminated 270 positions. Dutch biotech UniQure reduced its workforce by 65 percent (around 300 jobs). That included the sale of a Massachusetts manufacturing facility to Genezen. Denmark also felt the strain, with Leo Pharma cutting 250 roles as part of a strategic revamp. China emerged as another focal point of workforce reductions in 2024. Global pharmaceutical giants, such as Merck and Johnson & Johnson, restructured their operations in response to market complexities in the region. Local companies such as Connect Biopharma, which is transitioning to a US-focused company, also scaled back their presence in the country.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Amylyx, FibroGen, Lyra, Athira drastically reduce staff over setbacks in clinical trials Clinical trial failures were one of the most significant drivers of layoffs in 2024. For instance, Amylyx Pharmaceuticals faced a devastating blow when its amyotrophic lateral sclerosis (ALS) therapy, Relyvrio, failed a confirmatory trial. This led to a 70 percent reduction in its workforce, leaving only 100 employees from the 384 full-time staff reported at the end of 2023. The company’s decision to pull the therapy from the market compounded the layoffs. BioMarin Pharmaceutical had to reduce its workforce, as it streamlined its pipeline in response to trial challenges. In August, the company announced a reduction of 225 employees, citing “organizational redesign efforts”. These layoffs followed 170 redundancies announced earlier in May. FibroGen, once considered a leader in oncology drug development, was among the most heavily impacted. The high-profile failure of its anti-CTGF antibody in two late-stage cancer trials led to the discontinuation of its lead candidate, resulting in a 75 percent reduction in its US workforce. Lyra Therapeutics also implemented a 75 percent workforce reduction, affecting 87 employees, after its chronic rhinosinusitis program struggled. Similarly, Athira Pharma cut 70 percent of its team after its Alzheimer’s candidate failed a phase 2/3 trial.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Cash crunch, mergers compel Kronos Bio, Editas, Vincerx, Gilead to downsize In addition to clinical failures, funding constraints played a pivotal role in reshaping the biotech landscape. Kronos Bio stood out as one of the hardest-hit firms, cutting 21 percent and 83 percent of its existing workforce in March and November, respectively, as it sought to divest assets and conserve cash. Editas Medicine’s inability to secure partnerships for its sickle cell program forced the company to revert to preclinical research, resulting in a 65 percent workforce reduction. The trend of scaling back R&D pipelines was particularly evident among biotechs struggling to advance preclinical programs to clinical trials. Boundless Bio and Senti Bio exemplified this, choosing to focus on a handful of promising candidates, while reducing discovery efforts. Consolidation often results in overlapping roles, leading to inevitable workforce reductions. Apart from the MorphoSys layoffs by Novartis, Vincerx Pharma faced job losses after it got acquired by Oqory (a clinical-stage ADC company). Vincerx had to cut its workforce by 55 percent.  Amid ongoing reorganization efforts, Gilead closed its Seattle, Washington (US), office and laid off 72 employees of its subsidiary Kite Pharma. Gilead also announced that its Kite facility in Philadelphia, Pennsylvania (US), would close by mid-2025. That was followed by 104 additional layoffs at its California headquarters. In April, it had cut 58 jobs in California. Gilead also announced that its Kite facility in Philadelphia would close by mid-2025. Vir Biotechnology reduced its workforce by 25 percent (i.e. 140 layoffs) to focus on its hepatitis program, and GlycoMimetics let go of 80 percent of its workforce after the FDA demanded an additional clinical trial for its leukemia treatment. Meanwhile, Lexicon Pharmaceuticals reduced its workforce by 60 percent after it stopped commercial operations and transitioned back to being a clinical stage company.  View Our Interactive Dashboard on Biopharma Layoffs in 2024 (Free Excel Available)  Our view It takes decades to build innovation ecosystems. The concentration of layoffs in major biotech hubs has raised concerns about the potential long-term impact on these ecosystems. In 2025, the key challenge will be to maintain the momentum of innovation, as organizations operate with a leaner workforce and a more focused pipeline.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4560

    https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch

    #PharmaFlow by PHARMACOMPASS
    16 Jan 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Blackstone, Bain to Bid for Mitsubishi Pharma Unit in $3.5B Deal
    Blackstone, Bain to Bid for Mitsubishi Pharma Unit in $3.5B Deal

    13 Dec 2024

    // BUSINESS STD

    https://www.business-standard.com/world-news/blackstone-bain-to-bid-for-mitsubishi-pharma-unit-in-up-to-3-5-bn-deal-124121300731_1.html

    BUSINESS STD
    13 Dec 2024
    Share Share
    Mitsubishi To Present ND0612 Data At Parkinson Study Group Meeting
    Mitsubishi To Present ND0612 Data At Parkinson Study Group Meeting

    04 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-data-on-investigational-nd0612-at-the-2024-annual-meeting-of-the-parkinson-study-group-302321359.html

    PR NEWSWIRE
    04 Dec 2024
    Share Share
    Dewpoint collects new pharma partner for preclinical ALS program
    Dewpoint collects new pharma partner for preclinical ALS program

    04 Dec 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/mitsubishi-tanabe-inks-480m-biobucks-pact-dewpoint-preclinical-als-program

    FIERCE BIOTECH
    04 Dec 2024
    Share Share
    Dewpoint & Mitsubishi Tanabe Collaborate on ALS Treatment
    Dewpoint & Mitsubishi Tanabe Collaborate on ALS Treatment

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/04/2991446/0/en/Dewpoint-Therapeutics-and-Mitsubishi-Tanabe-Pharma-Corporation-Enter-Research-Collaboration-to-Advance-Small-Molecule-Condensate-Modulator-for-ALS.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share
    Martin License Docarpamine for Chronic Liver Disease From Mitsubishi
    Martin License Docarpamine for Chronic Liver Disease From Mitsubishi

    03 Dec 2024

    // #N/A

    https://www.prnewswire.com/news-releases/martin-pharmaceuticals-secures-exclusive-rights-from-mitsubishi-tanabe-pharma-for-docarpamine-to-treat-decompensated-chronic-liver-disease-including-ascites-302319798.html

    #N/A
    03 Dec 2024
    Share Share
    Mitsubishi Tanabe to Present ALS Research at MNDA Symposium
    Mitsubishi Tanabe to Present ALS Research at MNDA Symposium

    03 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-to-present-new-als-research-at-mndas-35th-international-symposium-on-alsmnd-302320119.html

    PR NEWSWIRE
    03 Dec 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Argatroban Monohydrate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Argatroban Monohydrate

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS JDMF arrow-down
    ✖

    Registration Number : 222MF10221

    Registrant's Address : 3-16-89 Kashima, Yodogawa-ku, Osaka City, Osaka Prefecture

    Initial Date of Registration : 2010-08-23

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Argatroban Monohydrate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Argatroban Monohydrate

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS JDMF arrow-down
    ✖

    Registration Number : 228MF10013

    Registrant's Address : Osaka Prefecture, Osaka City, Chuo Ward, Doshomachi 3-2-10

    Initial Date of Registration : 2016-01-08

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Diltiazem Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Diltiazem Hydrochloride

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 3059

    Submission : 1977-11-11

    Status : Inactive

    Type : II

     CEP/COS Inactive-api
    ✖

    Certificate Number : R1-CEP 2001-177 - Rev 05

    Issue Date : 2015-10-19

    Type : Chemical

    Substance Number : 1004

    Status : Withdrawn by Holder

     JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : HKINNOEN Co., Ltd.

    Registration Date : 2022-10-20

    Registration Number : 20221020-209-J-1386

    Manufacturer Name : Mitsubishi Tanabe Pharma Factory Ltd.

    Manufacturer Address : 7473-2, Ooaza Onoda, Sanyoonoda, Yamaguchi 756-0054, Japan

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Evocalcet

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Evocalcet

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS JDMF arrow-down
    ✖

    Registration Number : 229MF10027

    Registrant's Address : Osaka Prefecture, Osaka City, Chuo Ward, Doshomachi 3-2-10

    Initial Date of Registration : 2017-02-08

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Polyvinyl Alcohol API

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Polyvinyl Alcohol API

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2022-281 - Rev 02

    Issue Date : 2024-06-26

    Type : Chemical

    Substance Number : 1961

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Polyvinyl Alcohol API

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Polyvinyl Alcohol API

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2013-209 - Rev 00

    Issue Date : 2021-09-28

    Type : Chemical

    Substance Number : 1961

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Ursodeoxycholic Acid

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Ursodeoxycholic Acid

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 3312

    Submission : 1978-08-09

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    L-Threonine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    L-Threonine

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10061

    Submission : 1993-01-26

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Lysine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Lysine

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10062

    Submission : 1993-01-26

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Proline

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Biotech Showcase
    Not Confirmed
    arrow

    Proline

    Japan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biotech Showcase
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 10063

    Submission : 1993-01-26

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Excipients by Ingredients

    Upload your portfolio for free, ask us

    Excipients By applications

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Mitsubishi Tanabe Pharma and get a quotation

    Mitsubishi Tanabe Pharma is a supplier offers 57 products (APIs, Excipients or Intermediates).

    Find a price of Argatroban Monohydrate bulk with JDMF offered by Mitsubishi Tanabe Pharma

    Find a price of Diltiazem Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Evocalcet bulk with JDMF offered by Mitsubishi Tanabe Pharma

    Find a price of Ursodeoxycholic Acid bulk with DMF offered by Mitsubishi Tanabe Pharma

    Find a price of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Amino Acids Mixture bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Argatroban bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Aspartic Acid API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Cholebine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Coleneuramide bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Diltiazem Malate bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Carnitine Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Histidine Monohydrochloride Monohydrate bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Phenylalanine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Threonine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Dl-Tryptophan bulk offered by Mitsubishi Tanabe Pharma

    Find a price of DL-Valine API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Glycine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Isoleucine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Alanine API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Arginine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Arginine Hydrochloride API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Asparagine Monohydrate bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Cysteine Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Glutamic Acid bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Glutamine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Histidine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Leucine API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Threonine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Tyrosine API bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-Tyrosine Ethyl Ester Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of L-VALINE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Lysine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Lysine Acetate bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Lysine Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Methionine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Netoglitazone bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Osemozotan Hydrochloride bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Phenylalanine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Proline bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Serine bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Ta 3090 bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Thiopental Sodium bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Thyrotropin-Releasing Hormone bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Tryptophan bulk offered by Mitsubishi Tanabe Pharma

    Find a price of FACILS., PERSONNEL & GENERAL OPERATING PROCEDS-OF TOKYO,JAPAN PLANT bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Y-39983 DRUG SUBSTANCE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of HER.TIAZEPN bulk offered by Mitsubishi Tanabe Pharma

    Find a price of FACILS.,PERSONNEL, & GENERAL OPERATING PROCEDS-ONODA, JAPAN PLANT bulk offered by Mitsubishi Tanabe Pharma

    Find a price of MT-7716 DRUG SUBSTANCE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of MP-513 DRUG SUBSTANCE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of FACILS.,PERSONNEL, & GENERAL OPERATING PROCEDS-OF OSAKA, JAPAN PLANT bulk offered by Mitsubishi Tanabe Pharma

    Find a price of MP-124 DRUG SUBSTANCE bulk offered by Mitsubishi Tanabe Pharma

    Find a price of MCC-135 (BULK DRUG SUBSTANCE) bulk offered by Mitsubishi Tanabe Pharma

    Find a price of TA-5707F bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Aspirin bulk offered by Mitsubishi Tanabe Pharma

    Find a price of Aspirin Lysinate bulk offered by Mitsubishi Tanabe Pharma

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search